trimetazidine
Trimetazidine is a drug sold under many brand names for angina pectoris. Trimetazidine is described as the first cytoprotective anti-ischemic agent developed and marketed by Laboratoires Servier (France). It is an anti-ischemic (antianginal) metabolic agent of the fatty acid oxidation inhibitor class, meaning that it improves the heart muscle's ability to use glucose as a fuel by inhibiting its use of fatty acid metabolism. It has become controversial for its use as a performance-enhancing drug, with several scandals involving its use erupting at successive Olympic games. — Wikipedia
Clinical trial activity
33 trials · 45 clinical orgs · 0 marketing orgs
Earliest trial started Feb 1, 1999 (NCT00282360)
Timeline
Indications
Approved for
Studied for
- Acute Kidney Injury · Phase 4
- Acute-On-Chronic Liver Failure · Phase 1
- Amyotrophic Lateral Sclerosis · Phase 2
- Angina, Unstable · Phase 4
- Blood Platelet Disorders · Phase 2
- Carcinoma, Hepatocellular · Phase 3
- Cardiomyopathy, Hypertrophic · Phase 2
- Cardiotoxicity · Phase 2/Phase 3
- Coronary Artery Disease · Phase 4
- Coronary Disease · Phase 4
- COVID-19 · Phase 2
- Diabetes Mellitus · Phase 3
- Diabetes Mellitus, Type 2 · Phase 4
- Diabetic Cardiomyopathies · Phase 2
- Diabetic Nephropathies · Phase 2
- Drug-Related Side Effects and Adverse Reactions · Phase 1/Phase 2
- Fatty Liver · Phase 2
- Heart Diseases · Phase 4
- Heart Failure · Phase 1
- Heart Failure, Diastolic · Phase 4
- Hypertension, Pulmonary · Phase 2/Phase 3
- Ischemic Stroke · Phase 3
- Medicine, Chinese Traditional · Phase 4
- Microcirculation · Phase 4
- Motor Neuron Disease · Phase 2
- Myocardium · Phase 2
- Neoplasms · Phase 1
- Non-alcoholic Fatty Liver Disease · Phase 2
- Pathology · Phase 4
- Percutaneous Coronary Intervention · Phase 4
- Respiratory Distress Syndrome · Phase 2
- Vascular Resistance · Phase 4
Mechanism of action
- 3-ketoacyl-CoA thiolase, peroxisomalINHIBITOR
ACAA1 inhibitor
Chemistry & pharmacology
SMILES
COc1ccc(CN2CCNCC2)c(OC)c1OC- Mol. weight
- 266.34 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaTrimetazidine ↗
- ChEMBLCHEMBL3561076 ↗
- ChEMBLCHEMBL203266 ↗
Also known as
- 1-[2,3,4-trimethoxybenzyl] piperazine dihydrochloride
- 1-[2,3,4-trimethoxybenzyl] piperazine dihydrochloride
- trimetazidine
- trimetazidine
- trimetazidine
- trimetazidine
- trimetazidine
- trimetazidine
- trimetazidine
- trimetazidine
- trimetazidine dihydrochloride
- trimetazidine dihydrochloride
- trimetazidine dihydrochloride
- trimetazidine hcl
- trimetazidine hcl
- trimetazidine hcl
- trimetazidine hydrochloride
- vastarel
- vastarel
- vastarel
- vastarel mr
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06656442 | Phase 3 | Sep 1, 2024 | Ain Shams University |
| NCT06459193 | Phase 1/Phase 2 (Phase 2) | Jun 23, 2024 | Minia University |
| NCT06140953 | Phase 2 | Dec 10, 2023 | Beni Suef University, October 6 University |
| NCT06012708 | Phase 1 | Sep 30, 2023 | — |
| NCT05540184 | Phase 4 | Sep 30, 2022 | Beni Suef University, Cairo University |
| NCT05556005 | Phase 2 | Sep 18, 2022 | Ain Shams University |
| NCT05147194 | Phase 2 | Jan 1, 2022 | Huazhong University of Science and Technology |
| NCT05633563 | Phase 4 | Oct 1, 2021 | Aarhus University |
| NCT04788745 | Phase 2 | Jun 29, 2021 | FightMND, Julius Clinical, The Netherlands, Royal Brisbane & Women's Hospital, University of London, University of Queensland, Utrecht University |
| NCT04939857 | Phase 2/Phase 3 (Phase 3) | Jun 25, 2021 | Peking University |
| NCT04702906 | N/A | Feb 28, 2021 | Tanta University |
| NCT07074834 | N/A | Feb 1, 2021 | Shiyan City Renmin Hospital |
| NCT04760821 | Phase 2 | Dec 10, 2020 | Government of Brazil, University of Sao Paulo |
| NCT03809273 | Phase 4 | Jun 25, 2019 | China Medical University |
| NCT04661709 | Phase 4 | Jun 10, 2019 | China Academy of Chinese Medical Sciences, Government of China, National Natural Science Foundation of China |
| NCT03887013 | Phase 4 | Mar 25, 2019 | Chinese Academy of Medical Sciences |
| NCT03737448 | Phase 1 | Nov 28, 2018 | Martin Pharmaceuticals |
| NCT03715582 | Phase 3 | Oct 1, 2018 | University of Sao Paulo |
| NCT03504202 | N/A | Oct 1, 2018 | Huazhong University of Science and Technology |
| NCT03603249 | Phase 2 | Jul 1, 2018 | University of The West Indies |
Organizations
Research & Development (45)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| China Academy of Chinese Medical Sciences | Academic/Hospital | 3 | 3 | 1 | 2017 |
| Ain Shams University | Academic/Hospital | 2 | 2 | 2 | 2022 |
| Anyang Regional Hospital | Academic/Hospital | 2 | 0 | 1 | 2017 |
| Beni Suef University | Academic/Hospital | 2 | 1 | 2 | 2022 |
| First People's Hospital of Shangqiu | Academic/Hospital | 2 | 0 | 1 | 2017 |
| Huazhong University of Science and Technology | Academic/Hospital | 2 | 2 | 2 | 2018 |
| Jiaozuo third people's hospital | Academic/Hospital | 2 | 0 | 1 | 2017 |
| Luoyang Central Hospital | Academic/Hospital | 2 | 0 | 1 | 2017 |
| Nanyang Central Hospital | Academic/Hospital | 2 | 0 | 1 | 2017 |
| University of London | Academic/Hospital | 2 | 1 | 1 | 2012 |
| University of Sao Paulo | Academic/Hospital | 2 | 1 | 2 | 2018 |
| Xinxiang Medical University | Academic/Hospital | 2 | 0 | 1 | 2017 |
| Zhengzhou University | Academic/Hospital | 2 | 2 | 1 | 2017 |
| Aarhus University | Academic/Hospital | 1 | 1 | 1 | 2021 |
| British Heart Foundation | Academic/Hospital | 1 | 0 | 1 | 2012 |
| Cairo University | Academic/Hospital | 1 | 0 | 1 | 2022 |
| China Medical University | Academic/Hospital | 1 | 1 | 1 | 2019 |
| Chinese Academy of Medical Sciences | Academic/Hospital | 1 | 1 | 1 | 2019 |
| Clinical Hospital Center Zemun | Academic/Hospital | 1 | 1 | 1 | 2014 |
| Dalian Medical University | Academic/Hospital | 1 | 1 | 1 | 2017 |